MENU
Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Sep 24, 2023

Unlock Market Mastery: Tickeron's Top Robot Beats SP500 3 Weeks in a Row!

In these tumultuous times, where the S&P 500 has seen its fair share of turbulence for the third consecutive week, it's becoming increasingly clear that navigating the markets demands more than just intuition. That's why we're thrilled to introduce Tickeron's top-performing robot of the week – a powerhouse designed to outperform the S&P 500 even in the face of adversity.

Our cutting-edge robot has been on a winning streak, consistently beating the S&P 500 for three weeks straight, and it's ready to help you secure profits even when the market takes a dip. This is the solution you've been waiting for in this period of market uncertainty and heightened volatility.

Swing Trader, Popular stocks ($1.5K per position): Mixed Strategy (TA&FA)

Click to view full description and closed trades for free!

What sets Tickeron's robot apart is its unmatched complexity and formidable mathematical prowess. It's tailored for traders who aspire to match the success of seasoned hedge fund professionals, offering a potent combination of two proven strategies and advanced algorithms that will revolutionize your trading experience.

Long Position Strategy: Our first strategy is meticulously designed for long positions, with a keen eye on strategically identifying the perfect moments to exit stocks during sideways movements. This precision ensures you maintain an optimal profit-to-risk ratio, allowing you to capitalize on emerging trends right from their inception. With this strategy, you can confidently ride the market waves.

Short Position Strategy: For short positions, our robot excels at pinpointing reversal points in uptrends. This is achieved through a complex set of algorithms that scrutinize data on stock volatility and price dynamics. Armed with this knowledge, you can seize opportunities when market trends take a turn, turning market reversals into profitable ventures.

Don't let market uncertainty hold you back any longer. With Tickeron's cutting-edge robot, you'll have the power of sophisticated strategies and advanced algorithms at your fingertips. Trade confidently, track numerous trades simultaneously, and secure your path to success in even the most challenging market conditions.

Join the ranks of traders who are already benefiting from our innovative robot and start making your mark in the world of trading.

Here are the latest trades:

Related Ticker: ATOS, AQST, GNRC, MOS, BLDP

Aroon Indicator for ATOS shows an upward move is likely

ATOS's Aroon Indicator triggered a bullish signal on May 23, 2025. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 149 similar instances where the Aroon Indicator showed a similar pattern. In of the 149 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. of 67 cases where ATOS's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Momentum Indicator moved above the 0 level on June 27, 2025. You may want to consider a long position or call options on ATOS as a result. In of 85 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ATOS just turned positive on June 27, 2025. Looking at past instances where ATOS's MACD turned positive, the stock continued to rise in of 53 cases over the following month. The odds of a continued upward trend are .

ATOS moved above its 50-day moving average on June 24, 2025 date and that indicates a change from a downward trend to an upward trend.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where ATOS advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ATOS declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.739) is normal, around the industry mean (16.326). P/E Ratio (0.000) is within average values for comparable stocks, (58.407). ATOS's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.310). Dividend Yield (0.000) settles around the average of (0.041) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (252.768).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ATOS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ATOS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

Notable companies

The most notable companies in this group are Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Moderna (NASDAQ:MRNA), Arrowhead Pharmaceuticals (NASDAQ:ARWR), BioCryst Pharmaceuticals (NASDAQ:BCRX), Adaptive Biotechnologies Corp (NASDAQ:ADPT), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.3B. The market cap for tickers in the group ranges from 151 to 299.85B. NONOF holds the highest valuation in this group at 299.85B. The lowest valued company is MYMX at 151.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was 4%. For the same Industry, the average monthly price growth was 31%, and the average quarterly price growth was 13%. RKVTD experienced the highest price growth at 1,028%, while KLTO experienced the biggest fall at -53%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was 63%. For the same stocks of the Industry, the average monthly volume growth was 111% and the average quarterly volume growth was 145%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 84
Price Growth Rating: 60
SMR Rating: 92
Profit Risk Rating: 95
Seasonality Score: 8 (-100 ... +100)
View a ticker or compare two or three
MOS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a producer of phosphate and potash

Industry ChemicalsAgricultural

Profile
Fundamentals
Details
Industry
Chemicals Agricultural
Address
101 East Kennedy Boulevard
Phone
+1 800 918-8270
Employees
14049
Web
https://www.mosaicco.com